Amichetti M, Valentini A
Centro Oncologico Ospedale S. Chiara, Trento, Italy.
J Chemother. 1989 Feb;1(1):68-71. doi: 10.1080/1120009x.1989.11738867.
Forty-five patients with epidermoid cancer of the head and neck were either treated with cisplatin and bleomycin (DDP-BLM) or with vincristine, bleomycin and methotrexate (VBM) as neoadjuvant chemotherapy before radical radiation therapy (XRT). Chemotherapy with DDP-BLM provided a tumoral response of 80% [20% complete response (CR), 60% partial response (PR)]; VBM showed a response of 60% (12% CR, 48% PR). At the end of XRT-program (65 Gy total dose, 2-2.5 Gy dose per fraction, 5 times a week) complete response rates were similar in VBM-pretreated group (52.5%) and DDP-BLM pretreated group (50%). Analysis of survival shows no significant difference between the two inductive schemes: 8% vs 7.5% at 72 months. Our study suggests an increased initial response rate but no advantage in survival with combined therapy in comparison with standard XRT: long-term benefits were not apparent in these two groups of patients.
45例头颈部表皮样癌患者在根治性放射治疗（XRT）前接受了顺铂和博来霉素（DDP - BLM）或长春新碱、博来霉素和甲氨蝶呤（VBM）作为新辅助化疗。DDP - BLM化疗的肿瘤缓解率为80%[20%完全缓解（CR），60%部分缓解（PR）]；VBM的缓解率为60%（12% CR，48% PR）。在XRT疗程结束时（总剂量65 Gy，每次分割剂量2 - 2.5 Gy，每周5次），VBM预处理组（52.5%）和DDP - BLM预处理组（50%）的完全缓解率相似。生存分析显示两种诱导方案之间无显著差异：72个月时分别为8%和7.5%。我们的研究表明，与标准XRT相比，联合治疗的初始缓解率有所提高，但在生存方面并无优势：这两组患者均未显示出长期获益。
